📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-14 17:22
631 analysed today
631
Today
134,273
All-time analysed
40,194
Positive
6,287
Negative
79,947
Neutral
7,777
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
14 announcements match the current filters (relevance ≥ 5).
Ajooni Biotech Q1 Revenue Surges 103% YoY to Rs 63.49 Cr; PAT Drops 45% to Rs 0.43 Cr
Ajooni Biotech reported standalone revenue from operations of Rs 63.49 Cr for the quarter ended June 30, 2026, representing a 103% YoY growth compared to Rs 31.27 Cr in Q1 FY26. However, net profit declined 44.7% YoY to Rs 0.43 Cr (vs Rs 0.78 Cr in Q1 FY26) due to raw material costs jumping to Rs 54.55 Cr and rising finance costs of Rs 0.48 Cr. Profit before tax contracted to Rs 0.65 Cr from Rs 1.03 Cr in the year-ago period. Current borrowings rose sharply to Rs 25.50 Cr as of June 30, 2026, up from Rs 16.22 Cr as of March 31, 2026.
Confidence: HIGH
What changedAjooni Biotech reported Q1 standalone financial results reflecting strong revenue scaling alongside significant net margin contraction.
Why it mattersTop-line doubling shows increased volume processing from capacity additions, but elevated input costs and higher leverage are suppressing profitability.
Revenue from operations (Q1): Rs 6,349.07 LakhsNet Profit (Q1): Rs 43.18 LakhsCost of materials consumed: Rs 5,454.86 LakhsFinance costs: Rs 48.21 LakhsCurrent borrowings (as of 30.06.2026): Rs 2,550.27 Lakhs
📅 Short termMargin compression and doubling of finance costs are likely to dampen sentiment despite top-line growth.
📈 Long termLong-term re-rating relies on transitioning product mix into 9-10% margin animal feed supplements to build pricing power against input cost fluctuations.
⚠ Risk flags
- Severe margin compression from raw material price pressures
- Sharp increase in short-term debt and finance costs
- Limited pricing power in a fragmented compound feed industry
Key Highlights
Revenue from operations rose 103.1% YoY to Rs 63.49 Cr (Rs 6,349.07 Lakhs) from Rs 31.27 Cr (Rs 3,126.77 Lakhs) in Q1 FY26
Net profit fell 44.7% YoY to Rs 0.43 Cr (Rs 43.18 Lakhs) compared to Rs 0.78 Cr (Rs 78.14 Lakhs) in Q1 FY26
Cost of materials consumed escalated to Rs 54.55 Cr (Rs 5,454.86 Lakhs) compared to Rs 25.64 Cr in Q1 FY26
Current borrowings expanded by 57.2% to Rs 25.50 Cr (Rs 2,550.27 Lakhs) from Rs 16.22 Cr on March 31, 2026
👀 What to Watch
Track whether the company can expand higher-margin feed supplements to counter raw material cost inflation and control rising short-term borrowing levels.
Rs 63.49 Cr Revenue: Ajooni Reports 103% YoY Growth but 45% PAT Decline in Q1 FY27
Ajooni Biotech reported a significant 103% YoY revenue jump to Rs 63.49 Cr for the quarter ended June 30, 2026, compared to Rs 31.27 Cr in the previous year. However, Net Profit fell 45% YoY to Rs 0.43 Cr, down from Rs 0.78 Cr, primarily due to a sharp rise in finance costs and raw material expenses. The company's current borrowings increased by 57% during the quarter to Rs 25.50 Cr, while operating margins remain under pressure at approximately 1%.
Confidence: HIGH
What changedThe company has successfully scaled its revenue following capacity expansion, but profitability has been severely impacted by higher operational and interest costs.
Why it mattersFor a micro-cap company with thin margins (TTM OPM 3.4%), the sharp decline in PAT despite doubling revenue indicates a lack of pricing power and rising debt-servicing pressure.
Revenue (Q1 FY27): Rs 63.49 CrRevenue vs TTM Revenue: 34.9%Net Profit (Q1 FY27): Rs 0.43 CrCurrent Borrowings: Rs 25.50 CrFinance Costs (Q1 FY27): Rs 0.48 Cr
📅 Short termThe stock may face pressure as the market digests the margin contraction and the 55% QoQ decline in net profit.
📈 Long termStructural growth depends on whether the increased capacity can be utilized for higher-margin products rather than just low-margin compound feed.
⚠ Risk flags
- Sharp margin contraction
- Rising finance costs
- Significant increase in short-term debt
- Low promoter holding (26.9%)
Key Highlights
Revenue from operations increased 103% YoY to Rs 63.49 Cr from Rs 31.27 Cr.
Net Profit declined 45% YoY to Rs 0.43 Cr from Rs 0.78 Cr in Q1 FY26.
Finance costs surged 500% YoY to Rs 0.48 Cr from Rs 0.08 Cr.
Current borrowings rose to Rs 25.50 Cr from Rs 16.22 Cr in March 2026.
Property, Plant and Equipment increased by Rs 3.63 Cr to Rs 29.49 Cr, reflecting recent capex.
👀 What to Watch
Investors should monitor the company's ability to transition into high-margin (9-10%) feed supplements as planned, which is necessary to offset the rising interest burden and thin operating margins.
₹3.87 Cr Allotment: Ajooni Biotech Issues 90 Lakh Shares to Healthy Biosciences
Ajooni Biotech has approved the allotment of 90,00,000 equity shares at a price of ₹4.30 per share, aggregating to ₹3.87 crore. The allotment was made via a preferential issue to a single entity, Healthy Biosciences Limited. The issue price of ₹4.30 is notably higher than the current market price of ₹3.80. This capital infusion represents approximately 6.1% of the company's current market capitalization of ₹63 crore.
Confidence: HIGH
What changedThe company has completed a preferential allotment of 90 lakh shares, resulting in a capital infusion of ₹3.87 crore and a corresponding increase in the total outstanding equity.
Why it mattersThe fundraise provides immediate liquidity and strengthens the net worth (currently ₹91 Cr). The fact that the allotment happened at a premium to the market price suggests investor confidence in the company's shift toward high-margin feed supplements.
Total Allotment Value: ₹3.87 CrIssue Price per Share: ₹4.30Fundraise vs Market Cap: ~6.1%Fundraise vs Net Worth: ~4.2%Number of Shares Allotted: 90,00,000
📅 Short termThe allotment at a premium (₹4.30) relative to the current market price (₹3.80) is likely to be viewed as a positive signal by the market in the short term.
📈 Long termWhile the fundraise is relatively small compared to TTM revenue (₹182 Cr), it supports the company's stated goal of strengthening net worth and expanding capacity in the animal nutrition space.
⚠ Risk flags
- Equity dilution for existing shareholders
- Concentration of new shares with a single investor
Key Highlights
Allotment of 90,00,000 equity shares at an issue price of ₹4.30 per share
Total fundraise amount aggregates to ₹3,87,00,000 (₹3.87 crore)
Issue price includes a premium of ₹2.30 per share on a face value of ₹2
Single allottee for the entire issue: Healthy Biosciences Limited
👀 What to Watch
Investors should monitor the utilization of these funds, particularly whether they are deployed toward the company's planned ₹16.5 Cr factory expansion or to reduce the ₹18 Cr debt. Watch for the next shareholding pattern to see the impact on promoter vs. public holding.
90 Lakh Shares Preferential Issue Approved at Rs 4.30 per Share
Ajooni Biotech's shareholders have approved the issuance of 90,00,000 equity shares on a preferential basis at the 16th Annual General Meeting. The issue price of Rs 4.30 per share represents a premium over the current market price of Rs 4.0. This fundraise will inject approximately Rs 3.87 crore into the company, representing about 5.9% of its current market capitalization. The capital is likely intended to support the company's ongoing expansion into high-margin animal feed supplements.
Confidence: HIGH
What changedThe company has received formal shareholder approval to proceed with a preferential equity issue of 90 lakh shares.
Why it mattersThis provides a capital cushion to support the company's transition toward specialized feed supplements which offer higher margins (9-10%) compared to standard cattle feed. The issuance at a premium to the market price is generally a positive signal regarding internal valuation.
Shares to be issued: 90,00,000Issue Price: Rs 4.30Estimated Fundraise: Rs 3.87 CrFundraise vs Market Cap: ~5.9%Current Market Price: Rs 4.0
📅 Short termThe stock may see positive sentiment due to the preferential issue being priced at a premium to the current market price.
📈 Long termThe capital supports the company's strategy to reach a net worth of Rs 84 Cr and expand capacity, which is critical for achieving its 25-30% growth target.
⚠ Risk flags
- Equity dilution of approximately 5-6% for existing shareholders
- Utilization of funds depends on timely execution of the new factory project
Key Highlights
Approval for issuance of 90,00,000 equity shares on a preferential basis
Issue price fixed at Rs 4.30 per share, which is above the current market price of Rs 4.0
Total fundraise magnitude estimated at Rs 3.87 crore
Shareholder approval secured via special resolution at the AGM held on July 29, 2026
Fundraise represents approximately 4.25% of the company's current net worth of Rs 91 crore
👀 What to Watch
Investors should monitor the upcoming disclosure regarding the identity of the allottees (promoters vs. strategic investors) and the specific timeline for the deployment of these funds into the new production facility.
Ajooni Biotech AGM: Shareholders Approve Preferential Issue and Capital Increase
Ajooni Biotech concluded its 16th AGM on July 29, 2026, where shareholders voted on four key resolutions including a preferential issue of equity shares. This capital raise follows a strong FY26 performance where revenue grew ~59% to Rs 182.38 Cr. The company is currently executing a strategic shift toward high-margin (9-10%) feed supplements supported by a new Rs 16.5 Cr factory. Investors should note that while the fundraise supports growth, it will lead to equity dilution in a company with a relatively low promoter holding of 26.9%.
Confidence: HIGH
What changedThe company has obtained shareholder approval to proceed with a preferential share issuance and an increase in its authorized capital structure.
Why it mattersThis fundraise is critical for a micro-cap company (Rs 66 Cr market cap) to fund its Rs 16.5 Cr capacity expansion and transition into higher-margin product segments.
FY26 Revenue: Rs 182.38 CrMarket Cap: Rs 66 CrShareholders as of July 17, 2026: 60,449Planned Capex for New Factory: Rs 16.5 CrPromoter Holding: 26.89%
📅 Short termThe stock may see interest as the market anticipates the details of the new investors coming in through the preferential route.
📈 Long termIf the raised capital successfully operationalizes the new facility and shifts the product mix to 9-10% margin supplements, it could structurally re-rate the business.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Equity dilution from preferential issue
- Low promoter holding at 26.89%
- Susceptibility to raw material price spikes in maize and mustard
Key Highlights
Shareholders approved a special resolution for the issuance of equity shares on a preferential basis
Proposal to increase the authorized share capital was placed before the 60,449 shareholders of record
FY26 revenue reached Rs 182.38 Cr, a significant jump from Rs 114.68 Cr in FY25
The company is targeting a medium-term margin expansion to 4.5-6.0% through specialized supplements
The AGM proceedings were conducted via video conferencing and concluded within 21 minutes
👀 What to Watch
Watch for the detailed voting results and the specific terms of the preferential issue, including the issue price and the identity of the allottees, to assess dilution impact.
Ajooni Biotech to Raise ₹3.87 Cr via Preferential Issue; Proposes ₹20 Cr Capital Increase
Ajooni Biotech has scheduled its 16th Annual General Meeting for July 29, 2026, to seek approval for a preferential allotment of 90 lakh shares to its promoter, Healthy Biosciences Limited. The issue is priced at ₹4.30 per share, totaling ₹3.87 Cr, which represents approximately 2.1% of the company's TTM revenue. Additionally, the company proposes increasing its authorized share capital by ₹20 Cr to ₹70 Cr, providing headroom for future equity expansion. This move aligns with the company's stated strategy to strengthen its net worth and fund its shift toward high-margin feed supplements.
Confidence: HIGH
What changedThe company is initiating a promoter-led fund infusion and expanding its authorized capital limit to facilitate future growth and equity requirements.
Why it mattersThe promoter infusion of ₹3.87 Cr, while small relative to revenue, signals confidence and provides liquidity for the company's transition into specialized feed supplements with 9-10% margins.
Preferential Issue Size: ₹3.87 CrIssue Price per Share: ₹4.30Authorized Capital Increase: ₹20 CrIssue Size vs TTM Revenue: ~2.1%Issue Size vs Net Worth: ~4.25%AGM Date: July 29, 2026
📅 Short termThe stock may see neutral to slightly positive sentiment as the market processes the promoter's commitment at a specific price point.
📈 Long termThe increase in authorized capital and promoter support are structural steps toward the company's goal of scaling its animal nutrition business and improving OPM from the current 3.4%.
⚠ Risk flags
- Minority shareholder dilution
- Promoter holding is relatively low at 26.9%
Key Highlights
Preferential allotment of 90,00,000 equity shares to promoter entity Healthy Biosciences Limited
Issue price fixed at ₹4.30 per share, including a premium of ₹2.30 per share
Total fundraise amount of ₹3.87 Cr from the promoter group
Proposed increase in Authorized Share Capital from ₹50 Cr to ₹70 Cr
Relevant date for determining the minimum issue price set as June 29, 2026
👀 What to Watch
Monitor the shareholder vote on July 29, 2026, and subsequent allotment timeline to see if the funds are deployed toward the ₹16.5 Cr factory expansion slated for completion in FY26.
₹3.87 Cr Preferential Issue to Promoters; Stake to Increase to 30.53%
Ajooni Biotech's board has approved a preferential issue of 90 lakh equity shares to a promoter group entity, Healthy Biosciences Limited, at a price of ₹4.30 per share. This ₹3.87 crore infusion will increase the promoter holding from 26.89% to 30.53%, signaling increased promoter commitment. To facilitate this and future requirements, the company is also increasing its authorized share capital from ₹50 crore to ₹70 crore. The proposal is subject to shareholder approval at the upcoming AGM on July 29, 2026.
Confidence: HIGH
What changedThe company is raising equity capital specifically from its promoters, which will increase the total number of outstanding shares to 18.12 crore.
Why it mattersWhile the fundraise is small (approx. 2.1% of TTM revenue), the increase in promoter stake from a relatively low level (26.89%) is a positive signal of management's confidence in the company's shift toward high-margin feed supplements.
Total Issue Value: ₹3.87 CrIssue Price: ₹4.30Post-Issue Promoter Holding: 30.53%Fundraise vs TTM Revenue: ~2.1%New Authorized Capital: ₹70 Cr
📅 Short termThe market may view the promoter's decision to increase their stake at ₹4.30 as a floor for the stock price in the near term.
📈 Long termThe capital infusion supports the company's stated strategy to strengthen its net worth and transition into specialized animal nutrition, though the small scale of this specific raise suggests it is part of a larger funding mix.
⚠ Risk flags
- Small fundraise magnitude relative to expansion needs
- High public shareholding (69.47%) even after this issue
- Deferred decision on MD remuneration suggests ongoing internal reviews
Key Highlights
Preferential allotment of 90,00,000 equity shares to promoter group entity Healthy Biosciences Limited
Issue price fixed at ₹4.30 per share, representing a total fundraise of ₹3.87 crore
Promoter shareholding to increase by 3.64 percentage points to 30.53% post-issue
Authorized share capital increased by 40% from ₹50 crore to ₹70 crore
Public shareholding will be diluted from 73.11% to 69.47% following the allotment
👀 What to Watch
Investors should monitor the shareholder voting results from the AGM on July 29, 2026, and track the progress of the ₹16.5 Cr factory expansion previously slated for completion.
Ajooni Biotech FY26 Revenue Jumps 59% to ₹182.38 Cr; Annual Net Profit Rises 28%
Ajooni Biotech Limited reported a robust performance for the fiscal year ended March 31, 2026, with annual revenue from operations surging 59% to ₹18,237.81 lakhs. Full-year net profit grew by 28% to ₹432.19 lakhs compared to ₹337.20 lakhs in the previous year. However, the fourth quarter (Q4 FY26) showed margin pressure, with net profit declining to ₹94.72 lakhs from ₹154.38 lakhs YoY, despite a doubling of quarterly revenue. The company also saw a significant increase in current borrowings to ₹1,622.28 lakhs.
Key Highlights
Annual revenue from operations increased by 59.01% YoY to ₹18,237.81 lakhs.
Full-year net profit after tax rose 28.17% to ₹432.19 lakhs.
Q4 FY26 revenue doubled to ₹6,062.21 lakhs compared to ₹2,927.44 lakhs in Q4 FY25.
Annual Earnings Per Share (EPS) improved to ₹0.25 from ₹0.20 YoY.
Current borrowings increased significantly to ₹1,622.28 lakhs from zero in the previous fiscal year end.
👀 What to Watch
Investors should appreciate the strong top-line growth but remain cautious about the declining quarterly margins and the sharp rise in short-term debt. Monitor the company's ability to pass on rising material costs to maintain profitability.
Ajooni Biotech Secures Record ₹47.52 Cr Order; Triples Capacity to 1.8 Lakh MT
Ajooni Biotech has secured its largest-ever single order worth ₹47.52 crores for cattle feed from an existing customer, representing a significant portion of its current revenue. The company also announced the commissioning of its new Khanna plant, which increases total annual production capacity from 60,000 MT to 180,000 MT. For 9M FY26, the company reported a revenue of ₹122.87 crores and a PAT of ₹3.37 crores. Furthermore, the board is evaluating a potential merger with Healthy Biosciences Limited to drive inorganic growth.
Key Highlights
Received record-breaking order worth ₹47.52 crores for scientifically formulated cattle feed
Commissioned new facility in Khanna, Punjab, tripling total annual capacity to 1,80,000 MT
Reported 9M FY26 financial performance with ₹122.87 crore revenue and ₹3.37 crore PAT
Board is actively discussing the merger/amalgamation of Healthy Biosciences Limited with Ajooni
New plant technology expected to significantly reduce production costs and improve margins
👀 What to Watch
Investors should view the massive capacity expansion and record order book as strong growth catalysts for FY27. Monitor the progress of the proposed merger with Healthy Biosciences for potential synergy benefits.
Ajooni Biotech Bags Record ₹47.52 Cr Order; Total Capacity Reaches 1.8 Lakh MT
Ajooni Biotech has secured its largest-ever order valued at ₹47.52 crores from an existing client for cattle feed supply. This milestone coincides with the commissioning of a new plant in Khanna, Punjab, which triples the company's total annual production capacity to 1,80,000 MT. For the 9M FY26 period, the company reported a revenue of ₹122.87 crores and a PAT of ₹3.37 crores. Additionally, the board is exploring a strategic merger with Healthy Biosciences Limited to further consolidate its market presence.
Key Highlights
Secured the biggest-ever order in company history worth ₹47.52 crores.
Commissioned a new 1,20,000 MT plant, taking total capacity to 1,80,000 MT per year.
Reported 9M FY26 total revenue of ₹122.87 crores and PAT of ₹3.37 crores.
Board is currently evaluating a merger proposal with Healthy Biosciences Limited.
👀 What to Watch
Investors should monitor the company's ability to maintain margins with the new capacity and track the progress of the proposed merger. The significant order book provides strong revenue visibility for the upcoming quarters.
Ajooni Biotech Secures Major Cattle Feed Order Worth Rs. 47.52 Crores
Ajooni Biotech Limited has successfully secured a significant order valued at Rs. 47.52 crores for the supply of its scientifically formulated cattle feed. This order from a valued customer highlights the company's strengthening market position in the animal nutrition segment. The contract underscores growing demand and customer confidence in the company's product quality. This development is expected to provide a substantial boost to the company's revenue and operational scale in the near term.
Key Highlights
Received a new supply order worth Rs. 47.52 crores.
Order pertains to the supply of scientifically formulated cattle feed.
Strengthens the company's footprint in the animal nutrition industry.
Reflects robust demand and customer trust in product excellence.
👀 What to Watch
Investors should view this as a positive growth indicator and monitor the company's ability to execute this order efficiently. Watch for the impact on upcoming quarterly revenue and profit margins.
Ajooni Biotech Secures Significant Order Worth ₹47.52 Crores for Cattle Feed
Ajooni Biotech Limited has announced the receipt of a substantial order valued at ₹47.52 crores for the supply of its scientifically formulated cattle feed. This order from a valued customer highlights the growing demand for the company's animal nutrition products and strengthens its market position. The contract represents a significant milestone in the company's growth journey and reflects strong customer confidence in its product quality. This development is expected to contribute positively to the company's revenue and operational scale.
Key Highlights
Secured a major order worth ₹47.52 crores for cattle feed supply
Reinforces the company's presence in the specialized animal nutrition segment
Demonstrates strong customer trust and demand for scientifically formulated products
Significant milestone expected to drive future revenue growth
👀 What to Watch
Investors should view this as a positive growth indicator for the company's top-line and monitor the execution timeline of this order. The stock may see positive momentum given the substantial size of the order relative to the company's typical operations.
Ajooni Biotech Q3 Net Profit Jumps 125% YoY to ₹1.65 Cr; Merger Proposal Deferred
Ajooni Biotech reported a strong financial performance for the quarter ended December 31, 2025, with revenue from operations growing 72.6% YoY to ₹58.75 crore. Net profit for the quarter surged by 125.7% YoY to ₹1.65 crore, up from ₹0.73 crore in the same period last year. For the nine-month period, the company has already matched its previous full-year profit, reaching ₹3.37 crore. While the board discussed a merger with Healthy Biosciences Limited, the decision has been deferred for further evaluation, which remains a key watchpoint for future growth.
Key Highlights
Revenue from operations grew 72.6% YoY to ₹5,875.33 Lakhs in Q3 FY26.
Net profit for the quarter increased 125.7% YoY to ₹164.80 Lakhs.
9-month (Apr-Dec 2025) revenue reached ₹12,175.61 Lakhs vs ₹8,541.75 Lakhs YoY.
Earnings Per Share (EPS) for the quarter improved to ₹0.10 from ₹0.04 YoY.
Board deferred the merger proposal of Healthy Biosciences Limited pending further internal evaluation.
👀 What to Watch
Investors should take note of the significant top-line and bottom-line expansion; however, they should monitor updates regarding the deferred merger which could impact long-term valuation.
Ajooni Biotech Commences Production & Receives Orders Worth ₹27 Crores
Ajooni Biotech Limited has announced the commencement of commercial production at its newly installed manufacturing facilities in Khanna, Punjab. This expansion is expected to significantly contribute to the company's revenue and market presence. Furthermore, the company has secured new orders for cattle feed valued at ₹27 Crores, demonstrating strong customer trust in both domestic and export markets. Investors should monitor the impact of this increased production capacity and order fulfillment on the company's future financial performance.
Key Highlights
Commercial production commenced at newly installed manufacturing facilities.
Received new orders for cattle feed valued at ₹27 Crores.
New facility located in Khanna, Punjab.
👀 What to Watch
Investors should closely monitor Ajooni Biotech's revenue growth and profitability in upcoming quarters to assess the impact of the new production facility and order book. Review the company's quarterly reports for updates on capacity utilization and order execution.
